This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Sergliflozin

GlaxoSmithKline plc

Drug Names(s): KGT-1251, 869682

Description: 869682 is an inhibitor of the sodium-glucose co-transporter SGLT2, which is found in the intestines and in the kidney. It is responsible for the re-uptake of glucose into the bloodstream. Inhibition should lead to excess glucose being excreted in the urine. This should lower high glucose levels and lead to less excess glucose being converted into fat.

Deal Structure: In October 2002, GlaxoSmithKline was granted worldwide development and marketing rights, excluding Japan, Korea, China and Taiwan, for KGT-1251 (GSK 869682) from Kissei Pharmaceutical.

Partners: Kissei Pharmaceutical Co., Ltd


Sergliflozin News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug